

SP0050

Treatment recommendations and predictors in Eating DisordersF. Fernandez-Aranda^{1,2,3*}

Eating Disorders Section and Eating Disorders Section

¹Clinical Psychology, University Hospital of Bellvitge-IDIBELL;²CIBERobn, ISCIII and ³Clinical Sciences, University of Barcelona, Barcelona, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.97

Abstract: Eating disorders are severe mental disorders with a high mortality rate - suicidality - and a high incidence in adolescence and early adulthood, especially in women. The course of these disorders is uncertain and treatment outcomes are limited, with successful outcomes in 50-75% of cases. For bulimia nervosa (BN) and binge eating disorder (BED), several factors, such as duration of the disorder, eating and general psychopathology, dysfunctional personality traits and cognitive impairment, have been found to be associated with treatment adherence and response. In anorexia nervosa (AN) and atypical ED (OSFED), treatment response is poorer, with higher dropout rates and longer duration and chronicity. In this presentation, we will describe recent prospective observational studies in large samples of EDs analysing clinical, personality and cognitive predictors of treatment response in eating disorders, as well as potential associated neurobiomarkers. Optimisation of health care resources and transitions, as well as early and effective personalised treatments, can change the trajectory of EDs.

Disclosure of Interest: F. Fernandez-Aranda Grant / Research support from: We thank CERCA Programme/Generalitat de Catalunya for institutional support. We also want to thank the Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) and ISCIII (CIBERobn is its initiative). This research was supported by grants from Instituto de Salud Carlos III (ISCIII) (FIS PI20/00132) and co-funded by FEDER funds/European Regional Development Fund (ERDF), a way to build Europe. Additional support was received from the Delegación del Gobierno para el Plan Nacional sobre Drogas (2021I031) and Ministerio de Ciencia e Innovación (grant PID2021-124887OB-I00), but also AGAUR-Generalitat de Catalunya (2021-SGR-00824), European Union's Horizon 2020 research and innovation program under Grant agreement no. 847879 (PRIME/H2020, Prevention and Remediation of Insulin Multimorbidity in Europe) and the European Union's Horizon Europe research and innovation program under grant agreement No 101080219 (eprObes)., Consultant of: FFA received consultancy and speakers honoraria from Novo Nordisk.

SP0051

Treatment strategies in eating disorders with comorbid conditions and in under-represented clinical populations

G. Paslakis

University Clinic for Psychosomatic Medicine and Psychotherapy, Ruhr-University Bochum, Campus East-Westphalia, Luebecke, Germany

doi: 10.1192/j.eurpsy.2024.98

Abstract: Eating disorders (EDs) have long been thought to be conditions that only or mainly affect women, especially young, affluent, skinny girls and women in Western cultures. Mostly over the last decade, we have come to realize that EDs may affect individuals of all genders, ages, sexual orientations, ethnic, and socio-economic backgrounds. This, in turn, has implications for ED presentation and assessment, and the necessity for adjustments in the provided care according to diverse treatment needs. Here, we present and discuss current advances in ED-related research in underrepresented groups as well as the need to further incorporate diversity aspects in clinical care and research within the ED realm.

Disclosure of Interest: None Declared

SP0052

Reconceptualising depression along the endogenous-reactive spectrum: are different genes involved in depression depending on presence vs absence of exposure to stress?

X. Gonda

Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

doi: 10.1192/j.eurpsy.2024.99

Abstract: Depression is a complex and highly heterogeneous disorder with an omnigenic and multifactorial background. This diversity is obvious not only in its symptomatic manifestation but also in its neurobiological underpinnings which is one potential factor contributing to the high observed rate of treatment resistance. Thus, subtyping depressions, understanding their distinct neurobiological and genetic background, and potentially developing biomarkers aiding their differential diagnosis may bring us one step closer to more effective treatment. The present talk will overview the different etiological factors contributing to the emergence of depression along an endogenous-reactive continuum, the contributory roles of different types of stress, different genes involved in distinct processes, and the potential consequences of conceptualising, diagnosing and treating depressions developing in the context or independently of current stress.

Disclosure of Interest: None Declared

SP0053

Is bipolar mixed depression associated with a good response to psychotropic augmentation?

Z. Rihmer

Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary

doi: 10.1192/j.eurpsy.2024.100

Abstract: Is bipolar mixed depression associated with a good response to psychotropic augmentation? Zoltán Rihmer Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest

and at the National Institute of Mental Health, Neurology and Neurosurgery, Budapest, Hungary.

Introduction: Suboptimal response to antidepressant pharmacotherapy (nonresponse or partial response but no remission) is the most challenging issue in the treatment of depressive disorders. Open and controlled clinical studies show that augmentation of the given antidepressant with lithium, atypical antipsychotics, antiepileptics and thyroid hormones are effective in 30-40% in such cases.

Objectives: To explore the possibility whether bipolar mixed depression is the ideal subject of good response to psychotropic augmentation.

Method: Literature review.

Results: Studies consistently indicate that in contrast to unipolar MDE (=MDD) the rate of antidepressant-resistant depression is higher not only in bipolar I and II depression but also in MDE with subthreshold bipolarity (bipolar mixed depression). However, lithium, atypical antipsychotic and antiepileptic (but not thyroid) augmentation works much better in bipolar depression and in unipolar MDE with subthreshold bipolarity (mixed depression) than in unipolar MDE without subthreshold bipolar features. In addition to this, almost all clinical predictors of good response to lithium/atypical antipsychotics/antiepileptics are classical bipolar markers (familial bipolarity, early onset, intradepressive hypomanic symptoms, agitation, cyclothymic temperamental, shorter episodes, more than three depressive episodes, and suicidality).

Conclusion: Considering that lithium, atypical antipsychotics and antiepileptics, but not thyroid stimulating drugs have more and less antimanic effect, these results suggest that treating intradepressive hypomanic symptoms in bipolar mixed depression is a new (if not the only) explanation among the several previously proposed mechanisms of action of successful psychotropic augmentation of antidepressants in patients with MDE.

Disclosure of Interest: None Declared

SP0054

Suicidal behavior in combat veterans with mood disorders

L. Sher^{1,2,3*}

¹James J. Peters VA Medical Center; ²Icahn School of Medicine at Mount Sinai and ³Columbia University Vagelos College of Physicians and Surgeons, New York, United States

*Corresponding author.

doi: 10.1192/j.eurpsy.2024.101

Abstract: Introduction. Military conflicts are ubiquitous. There are many combat veterans around the world. The combat environment is characterized by violence, physical strains, separation from loved ones, and other hardships. Mood disorders and suicidality in combat veterans are a large and important issue.

Objectives: To discuss the pathophysiology and prevention of suicidal behavior in combat veterans with mood disorders

Methods: A review of the literature on suicidal behavior in combat veterans with mood disorders including own publications.

Results: Combat deployment may lead to multiple emotional, cognitive, psychosomatic symptoms, mood disorders, suicidal ideation and behavior. Pre-deployment, deployment and post-deployment adversities may increase risk of mood disorders and suicide in combat veterans. The act of killing in combat is a stressor which may raise suicide risk. Combat-related injuries are associated with significantly increased depression and suicide risk. Post-deployment difficulties of reintegrating into civilian life may lead to depression and suicidality. Studies suggest that suicidal behavior in combat veterans may have a neurobiological basis. Prevention of mood disorders and suicide among combat veterans should include pre-deployment screening to exclude individuals with psychiatric disorders; psychological support and prevention of harassment and/or abuse during deployment; psychosocial support after deployment; diagnosing and treating psychiatric and medical disorders including neurological disorders; frequent depression and suicide screening; education of mental and non-mental health clinicians, war veterans, their families and friends regarding signs/symptoms of mood disorders and suicidality; and restriction of access to lethal means.

Conclusion: Combat veterans are a unique population. They are frequently exposed to psychological, physical, and biological factors which are unusual for civilians or non-combat military veterans. We need to study the specific psychobiology of combat veterans to understand how to develop effective depression and suicide prevention interventions for this population.

Disclosure of Interest: None Declared